• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a polyphenolic extract of passionflower seeds, in particular seeds of Passiflora incarnata or Passiflora edulis, comprising at least 30% by weight of polyphenols, expressed as gallic acid equivalent, relative to the weight of the 'dry extract. The invention also relates to a process for preparing such an extract, to a composition comprising it and to its cosmetic, dermatological or therapeutic use.
    公开号:FR3045380A1
    申请号:FR1562949
    申请日:2015-12-21
    公开日:2017-06-23
    发明作者:Sophie Leclere-Bienfait；Stephanie Bredif
    申请人:Laboratoires Expanscience；
    IPC主号:
    专利说明:

    The invention relates to an extract of passionflower seeds, Passiflora incarnata or edulis and preferably edulis, particularly rich in polyphenols and a process for the preparation of such an extract. The present invention also relates to the cosmetic, dermatological or therapeutic use of such a composition or of such an extract. The invention finally relates to a method of cosmetic care of the skin, superficial body growths or mucous membranes, comprising administering such a composition or such an extract.
    PASSIFLORES
    The passiflora family (Passiflora) consists of about 500 species. Species are often distributed in warm temperate and tropical regions, particularly in the Americas, but are rather rare in Asia, Australia and tropical Africa. Botanical
    Plants come in the form of shrubs or climbing grasses. The leaves are alternate, sometimes simple, lobed or webbed. The flowers can wait 9 cm in diameter, are bisexual or unisexual and regular. They are white and purple and have fine petaloid appendages, trimmed with filiform appendages symbolizing the crown of thorns of Christ. The fruit 4 to 5 cm long is oval and often yellow to orange.
    The most common species include Passiflora incarnata (P. incarnata) and Passiflora edulis (P. edulis).
    Elements of Phytochemistry P. incarnata: the major constituents are represented by the family of flavonoids which are present in large quantities in the leaves. The leaves contain, in particular, a high content of isovitexin. The leaves of P. incarnata also contain small quantities of simple indole alkaloids (harmane, harmine ...), sugars such as raffinose, sucrose, fructose, glucose, and essential oils and maltol described as the molecule that would be at the origin of the sedative and anti-convulsive effects attributed to this plant. P. edulis: from a methanolic extract of dried leaves, a specific compound has been identified: the passiflorin - cyclopropane triterpene glycoside (E. Bombardelli et al., 1975).
    The leaves of P. edulis contain in particular isoorientine, a flavonoid that is not found in the species P. incarnata. They also contain traces of essential oil and alkaloids identical to the P. incarnata species.
    The fruit pulp contains flavonoids, schaftoside, isoschaftoside, isoorientine, orientine, isovitexine, luteolin derivatives (M. L. Zeraik, J. H. Yariwake - 2010), ascorbic acid (about 60 mg / 100 g).
    The pulp also contains glycosylated cyanogenic derivatives: prunasin, sambunigrin and amygdalin, as well as two newly identified β-rutinoside mandelonitrile (Chassagne and Crouzet, D. 1998, D.S. Seigler, 2002).
    Toxicolosie
    Cyanogenic constituents are present mainly in the aerial parts of different varieties of passionflower.
    Characteristics of the godfather
    The seeds constitute 6 to 12% of the fruit of P. Edulis and they contain: - Polvphenols including Piceatannol (resveratrol-like structure) and scirpusin B dimer (S. Sano, K. Sugiyama, T. Ito, 2011) substances with vasorelaxant and antioxidant effects. - oil (18% yield after extraction with solvent) containing phytosterols (0.2% including campesterol, stigmasterol, sitosterol, avenasterol); 60 to 73% of linoleic acid (omega 6), 14% to 20% of oleic acid and 465 ppm of tocopherols (Piobom G., Barou et al., 2006, R. of V.V. Lopes et al.). - sugars and proteins. PRIOR ART Food Use
    The fruit seems to have been consumed since prehistory. In the 16th century in Peru, the beautiful flowers of passiflora were already considered a cure and many species of passiflora are still used in many countries in the current therapeutic practices.
    Medical use
    Passiflora (often aerial parts and sometimes fruit) are often used all over the world as anxiolytic, sedative, diuretic or analgesic ("Passiflora: review update, K. Dhawan, S. Dhawan, A. Sharma, 2004"). Maltol and some of its derivatives are at the origin of this sedative effect.
    This activity would be more constant and more significant for P. incarnata.
    Extracts of P. incarnata would be able to fight against addiction to morphine.
    An anti-hypotensive effect of a methanolic extract of P. ediilis fruit bark, as well as a hypocholestemic effect of a delipidated extract rich in fiber were also highlighted.
    An anti-tumor effect of a fruit decoction via the inhibition of matrix metalloproteinases (MMP2 and MMP9) involved in tumor invasion, metastasis and angiogenesis has also been demonstrated (S.S. Patel, 2009).
    Dermo-cosmetic uses
    In Brazil, leaves of P. foetida are used topically to treat skin diseases of inflammatory origin, particularly through the presence of isoorientine. In Mauritius and Rodrigues, leaf decoctions of P. suberosa are also used in baths to treat skin diseases.
    DESCRIPTION OF THE INVENTION
    The Applicant has discovered that the extracts of passionflower seeds, in particular Passiflora incarnata or Passiflora edulis, and advantageously Passiflora edulis, have cosmetic, pharmaceutical and dermatological properties never described so far. In particular, it is the first time that such extracts of passionflower seeds are used as such for their specific properties. The subject of the invention is thus a polyphenolic extract of Passionflower seeds, in particular seeds of Passiflora incarnata or Passiflora edulis, more particularly of Passiflora edulis, comprising at least 30% by weight of polyphenols, expressed in gallic acid equivalent. , based on the weight of the dry extract. This content is equivalent to at least 3 mg of polyphenols per milliliter of liquid extract. The extract according to the present invention advantageously comprises at least 35% by weight of polyphenols, expressed as gallic acid equivalent, relative to the total weight of said solids, that is to say at least 3.5 mg of polyphenols. per milliliter of liquid extract. The extract according to the present invention more advantageously comprises at least 40% by weight of polyphenols, expressed in gallic acid equivalent, relative to the total weight of said solids, that is to say at least 4 mg of polyphenols per ml of liquid extract.
    Among the polyphenols present in the extract according to the invention, there are mainly catechin derivatives.
    For the purposes of the present invention, catechol derivatives are understood to mean flavoinoids of the catechol family, also known as catechol. The catechin derivatives are more particularly compounds of the following general formula (I):
    (I) wherein: ------ represents a single bond of R or S configuration;
    R 1 represents OH or a galloyl group of formula (II) below:
    (Π); and R2 is H or OH.
    The catechin derivatives are more particularly compounds of general formula (I) chosen from the group consisting of:
    The extract according to the invention advantageously comprises at least 20% by weight, in particular at least 24% by weight of catechin derivatives, expressed as gallic acid equivalent, relative to the weight of the dry extract. Thus, in the extract according to the invention, at least 50% by weight, in particular at least 60% by weight, of the polyphenols are catechin derivatives, expressed in gallic acid equivalent, relative to the weight of polyphenols in the polyphenols. dry extract.
    Advantageously, the extract according to the invention also comprises at least 10% by weight of organic acids, in particular of acetic acid, of malic acid, of citric acid or their mixtures, relative to the weight of the extract. dry. The extract according to the invention is advantageously obtained by solid / liquid extraction of passionflower seeds in a solvent chosen from water, glycerol, glycols, and mixtures thereof.
    The solvent is more particularly chosen from water / glycerol binary mixtures, water / glycol, and mixtures thereof, advantageously in a proportion of between 30 and 90% of glycerol and / or of glycol in water.
    Preferably, the solvent used is chosen from water / glycerol or water / propanediol binary mixtures, in particular water / propanediol, more particularly water / 1,3-propanediol.
    In particular, the extract according to the invention advantageously contains, by weight relative to the dry extract obtained: approximately 40% of polyphenols; - About 10% of sugars; - About 11% of fruit acids; and - About 5% protein.
    In particular, the extract according to the invention does not include isoorientine, orientine, vitexine or isovitexine. The subject of the invention is also a process for the preparation of a polyphenol extract of passionflower, in particular of seeds of Passiflora incarnata or of Passiflora edulis, advantageously of Passiflora edulis, comprising at least 30% by weight of polyphenols, expressed in equivalent terms. gallic acid, based on the weight of the dry extract, said process comprising at least one solid / liquid extraction step in a solvent selected from water, glycerols, glycols, and mixtures thereof.
    Advantageously, said process for preparing a polyphenolic extract of passionflower seeds according to the invention comprises the following successive stages: a) crushing of the seeds; b) optionally delipidation of seeds, preferably by pressing, ethanolic extraction or CO2 extraction; c) solid / liquid extraction of crushed seeds and optionally delipidated in a solvent selected from water, glycerols, glycols, and mixtures thereof; d) separation of the solid phase and the liquid phase by decantation, and / or centrifugation and / or successive filtrations; e) optionally drying the extract obtained in step d). The step a) of grinding the seeds can be carried out by methods known to those skilled in the art, in particular by means of a knife mill, a hammer mill, etc. In step c), the solid / liquid extraction phase is preferably carried out at a temperature of between 20 ° C. and 90 ° C., in particular between 30 ° C. and 80 ° C., more particularly between 45 ° C. and 75 ° C, typically 70 ° C.
    The extraction time is advantageously between 30 minutes and 4 hours, in particular between 1 and 3 hours, advantageously it is about 2 hours.
    Advantageously, the extraction solvent used in stage c) is chosen from water / glycerol binary mixtures, water / glycol, and their mixtures, advantageously in a proportion of between 30 and 90% of glycerol and / or of glycol in the water. In particular, the extraction solvent is chosen from water / glycerol or water / propanediol binary mixtures, in particular water / propanediol, more particularly water / 1,3-propanediol.
    In an advantageous variant of the process, prior to step c), the passionflower seeds are delipidated. Before being dispersed, the crushed seeds can be delipidated, in particular in ethanol. The elimination of lipids allows a better efficiency of the extraction and filtration steps. It is also and preferably possible to use cakes from these seeds, that is to say the residue from the prior extraction of the oil by solvent, supercritical CO2 technique for example and preferably by mechanical pressing. Step d) of separation of the solid phase and the liquid phase is carried out by methods known to those skilled in the art, in particular by decantation, centrifugation and / or successive filtrations to perfect clarity and microbiological cleanliness.
    Advantageously, the polyphenolic extract according to the invention can be stabilized by the drying step e), by methods known to those skilled in the art. The drying step may, for example, be carried out in the presence of a support of the type, for example, maltodextrins or acacia fibers (Fibregum® company CNI). The support content typically varies in a ratio ranging from 0% to 80% of support relative to the percentage of dry matter obtained in the liquid form of the extract. The extract is preferably dried by lyophilization in order to obtain a final powder. The final powder advantageously comprises 30 to 70% by weight of dry matter of the extract, the 100% complement being the freeze-drying support. More advantageously, the final powder comprises 50% dry matter from the extract and 50% freeze-drying support.
    Alternatively, the starting raw material of the process according to the invention may be a cake of delipidated passionflower seeds, in particular by pressing. In this context and by way of non-limiting example, the polyphenolic extract according to the invention can be obtained according to the following process: a ') dissolving delipidated passionflower seed cake by pressing, at 10% dry matter content in water ; b ') solid / liquid extraction with stirring for 2 hours at a temperature of 70 ° C; c ') stepwise purification of successive filtrations; and sterile filtration. The extract obtained by the process according to the invention, as described in the preceding paragraphs, advantageously comprises at least 35% by weight, more advantageously at least 40% by weight, of polyphenols, expressed in gallic acid equivalent, by relative to the weight of the dry extract.
    Advantageously, the extract obtained by the process according to the invention comprises at least 20% by weight, in particular at least 24% by weight of catechin derivatives, expressed in gallic acid equivalent, relative to the weight of the dry extract. . Thus, in the extract obtained by the process according to the invention, at least 50% by weight, in particular at least 60% by weight, of the polyphenols are catechol derivatives expressed in gallic acid equivalent, relative to the weight of polyphenols. in the dry extract.
    Advantageously, the extract obtained by the process according to the invention comprises at least 10% by weight of organic acids, in particular of acetic acid, of malic acid, of citric acid or their mixtures, relative to the weight of the product. 'dry extract.
    The present invention therefore also relates to an extract of passionflower seeds, in particular seeds Passiflora incarnata or Passiflora edulis, preferably Passiflora edulis, obtainable by the method mentioned above. Such an extract meets the specifications defined above concerning the extract according to the invention.
    In the remainder of the description, reference will be made to "extract according to the invention" to designate the extract as such, as defined above, or the extract obtainable by the process according to the invention. invention as described above. The invention further relates to a composition comprising a polyphenol-rich extract of passionflower seeds according to the invention, as active ingredient, and optionally a suitable excipient. The extract according to the invention is as defined in the above paragraphs relating to the extract as such and those relating to the extract obtainable by the process according to the invention.
    The composition according to the invention advantageously comprises from 0.001 to 10% by weight, advantageously from 0.01 to 5% by weight, of said polyphenol extract of Passionflower seeds according to the invention, the weight of the extract being expressed as dry extract. , relative to the total weight of the composition.
    The composition is advantageously cosmetic, pharmaceutical or dermatological. The said composition is preferably formulated to be administered externally.
    The composition according to the invention may further comprise one or more other active ingredients.
    The composition according to the invention can be formulated in the form of different preparations adapted for topical administration.
    In particular, the topical compositions may especially be creams, emulsions, milks, ointments, lotions, oils, aqueous or hydro-alcoholic or glycolic solutions, powders, patches, sprays, shampoos, varnish or any other product for external application.
    Depending on its nature (cosmetic, dermatological or pharmaceutical), the composition according to the invention may further comprise at least one cosmetically, pharmaceutically or dermatologically acceptable excipient. In particular, the composition according to the present invention may further comprise at least one adjuvant cosmetically, pharmaceutically or dermatologically known to those skilled in the art, chosen from surfactants, thickeners, preservatives, perfumes, dyes, chemical filters or minerals, moisturizers, thermal waters, etc. The person skilled in the art knows how to adapt the formulation of the composition according to the invention by using his general knowledge.
    The modes of administration, the dosages and the optimal dosage forms of the compositions according to the invention can be determined according to the criteria generally taken into account in the establishment of a pharmaceutical, dermatological or cosmetic treatment adapted to a patient or an animal. , such as the age or body weight of the patient or animal, the severity of his general condition, the tolerance to treatment, the side effects noted, the type of skin. The subject of the invention is also an extract according to the invention or a composition according to the invention for its use for preventing and / or treating disorders or pathologies of the skin and / or mucous membranes and / or integuments, advantageously reactions inflammatory reactions, oxidation reactions, disorders related to radical attacks related or not to pollution, disorders of the barrier or homeostasis, aging, in particular chronological and / or actinic aging, of the skin and / or or mucous membranes and / or integuments. The subject of the invention is also an extract according to the invention or a composition according to the invention for its use for preventing and / or treating vascular disorders and / or adipose tissue alterations. The subject of the invention is also the use of an extract of seeds of passiflora according to the invention or of a composition according to the invention, for the manufacture of a cosmetic, pharmaceutical or dermatological composition for preventing and / or treating disorders or pathologies of the skin and / or mucous membranes and / or integuments, advantageously inflammatory reactions, oxidation reactions, disorders related to radical attacks related or not to pollution, disorders of the barrier or homeostasis, aging, in particular chronological and / or actinic aging, of the skin and / or mucous membranes and / or integuments. The subject of the invention is also the use of an extract of seeds of passiflora according to the invention or of a composition according to the invention, for the manufacture of a cosmetic, pharmaceutical or dermatological composition for preventing and / or treating vascular disorders and / or adipose tissue alterations. The invention further relates to a method for preventing and / or treating disorders or pathologies of the skin and / or mucous membranes and / or integuments, advantageously inflammatory reactions, oxidation reactions, disorders related to radical attacks linked or not to pollution, barrier or homeostasis disorders, aging, in particular chronological and / or actinic aging, of the skin and / or mucous membranes and / or integuments, including administration , especially the topical administration of an effective amount of a passive-leaved seed extract according to the invention or a composition according to the invention, to a subject in need thereof. The invention furthermore relates to a method for preventing and / or treating vascular disorders and / or adipose tissue disorders, comprising administering, in particular topical administration, an effective amount of a seed extract of passiflores according to the invention or a composition according to the invention, to a subject in need.
    In particular, the composition or the extract according to the invention is intended for the prevention and / or treatment of inflammatory reactions, oxidation reactions, disorders related to radical attacks related to environmental stress, such as pollution, UV, cigarette, etc., disorders of the barrier or homeostasis, aging, in particular chronological and / or actinic aging, of the skin, superficial body growths (hair and nails) and / or mucous membranes (gingiva, periodontitis, genital mucosa) immature, normal, mature or old.
    In particular, the composition or the extract according to the invention is intended for the prevention and / or treatment of disorders related to inflammatory and / or radical reactions caused by UV exposures, and / or to pollutants or intrinsic reactions, and thus causing accelerated aging, barrier disorders, vascular disorders, redness, etc.
    In particular, the composition or the extract according to the invention is intended (e) to fight against aging of the skin, especially against chronological aging and / or actinic.
    The disorders or pathologies of the skin mentioned above are more particularly vascular disorders, atopic dermatitis, eczema, irritative dermatitis, sensitive skin, reactive skin, skin with redness, erythema dermal, aged or photoaged skin, photosensitized skin, sunburns and inflammations due to rays of all kinds. The invention also relates to a process for the cosmetic care of the skin and / or superficial body growths and / or mucous membranes, with a view to improving their state and / or their appearance, consisting in administering a composition or an extract according to the present invention, advantageously by external topical route. The invention relates to a method for the cosmetic care of the skin, with a view to preventing aging, comprising applying to the skin a composition or an extract according to the present invention.
    The following examples illustrate the invention.
    DESCRIPTION OF THE FIGURES
    Figure 1 shows the percentage activation of NrF2 by an extract according to the invention.
    Figure 2 shows Immunolabeling of Claudine 4 in BaP-treated skin explants (Protocol 1)
    Figure 3 shows Immunolabeling of filaggrin in BaP + Nicotine-treated skin explants (Protocol 2)
    Figure 4 shows Immunolabeling of loricrin in BaP + Nicotine-treated skin explants (Protocol 2)
    Figure 5 shows Immunolabelling of Collagen I in BaP + Nicotine-treated skin explants (Protocol 2)
    Figure 6 depicts Immunolabeling of Elastin in BaP-treated skin explants (Protocol 1)
    Figure 7 shows Immunolabeling of fibronectin in BaP-treated skin explants (Protocol 1)
    Figure 8 shows the comet visual appearance after electrophoresis of normal processed human keratinocytes. Figure 8A corresponds to a negative control sample, Figure 8B to a UV control sample and Figure 8C to an extract according to the invention to 0.001%.
    EXAMPLE
    Example 1 Extract According to the Invention
    A polyphenolic extract is obtained according to the following process: a) dissolving of the cake of passionflower seeds delipidated by pressing and crushed, with 10% of dry matter in a mixture 1,3-propanediol / water 70/30 w / w ; b) extraction with stirring for 2 h at 70 ° C .; c) removal of the residual plant by coarse filtration; and d) purification of the extract obtained by filtrations including additional sterile filtration. The liquid polyphenolic extract thus obtained has the following characteristics (% on Dry Extract): • Dry extract (oven): 0.9% (m / m) • Total polyphenol content (by spectrophotometry - gallic acid equivalent): 43 % • Catechin derivative content (by HPLC - in gallic acid equivalent): 22.3% • Malic acid content (per enzymatic kit): 5.4% • Citric acid content (per enzymatic kit): 3.7% • Protein content (by Kjeldahl x 6.25): 4.5%
    Example 2 Extract According to the Invention
    A polyphenolic extract is obtained according to the following process: a) dissolving 13.3% non-delipidated Passiflorum edulis seeds and crushed in a 1,3-propanediol / water 70/30 mixture
    b) extraction with stirring for 2 h at 70 ° C. c) elimination of the residual plant by coarse filtration d) purification of the extract obtained by filtration, including additional sterile filtration. The liquid polyphenolic extract thus obtained has the following characteristics (% on Dry Extract): • Dry extract (oven): 1.07% (m / m) • Total polyphenol content (by spectrophotometry - gallic acid equivalent): 40% • Content in Proteins (Kjeldahl x 6.25): 5.7%
    EXAMPLE 2 Biological Activity of the Extract According to the Invention 1. Biological Potential
    The biological potential of an extract according to the invention was sought by means of a modulation test of gene expression on normal human fibroblasts (FHN) and on reconstructed and melanized human epidermis.
    Thus, the expression of 46 genes involved in various physiological pathways of the epidermis (barrier, pigmentation, inflammation ...) and the dermis (healing, elasticity, firmness ...) was studied by PCR-array.
    Material and methods :
    Normal human fibroblasts (FHN) and melanized reconstructed epidermis were incubated for 24 h in the presence of an extract according to the invention, as obtained in Example 1, at 0.002% and 0.05% (w / v). ) for the FHN or 0.002% and 0.005% (w / v) for the reconstructed epidermis, and in the presence of TGF-βΙ at 20ng / ml on the FHN or in the presence of Vitamin D3 at 1nM on the reconstructed epidermis ( validation of the tests).
    At the end of the treatment, the RNAs were extracted and the gene expressions were analyzed by qRT-PCR using TaqMan card targeting the key functions of the dermis and the epidermis. Results and conclusion:
    The results are presented in Tables 2 and 3 below and show in particular that the extract according to the invention, by varying the gene expression of certain markers, is of particular interest in the following activities: homeostasis and the structure of the dermal extracellular matrix (^ 1 MMP3); and - the Dermo-Epidermal Junction (71 LAMC2).
    More particularly, the polyphenols of the extract according to the invention have made it possible to modulate the gene expression of genes involved in the antioxidant defenses and the phenomenon of Hormesis (71 HMOX1, FTL and G6PD).
    This demonstrates that the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
    Table 2 - Screening on FHN
    * Level of gene expression expressed in relative amount (RQ) versus untreated control = 7
    Table 3 - Screening on reconstructed Epiderms
    * Level of gene expression expressed as relative (RQ) relative to untreated control = 1 2. Inducing activity of THormesis and cellular detoxification A Hormetic molecule (or Hormetin) is a substance with a biphasic effect, which at low dose will have a beneficial effect but in high doses will have the opposite effect (eg Prooxidant or Antioxidant). Hormetin is also described as a molecule reproducing the effects of a slight stress on the body but which in return will allow the cell to protect itself from future attacks and thus protect the body from various diseases (cancers) or phenomena age-related physical problems (skin aging, poor scarring ...) or harmful effects of the environment (UV, pollution ...).
    The following analyzes make it possible to study the inducing activity of THormesis and the cellular detoxification of an extract according to the invention. A-Activation of the Translocation of the NrF2 Transcription Factor: The Effect of the Extract According to the Invention Was Evaluated with Regard to the Activation of the Nrf2 Translocation, Precursor of the Cascade Responsible for the Hormone Response and some ways of detoxifying the body.
    Material and methods
    HaCaT keratinocytes transfected ARE-Luciferase, containing the plasmid Nqol Antioxidant Response Element (ARE) which is a plasmid specific for the activation of NrF2 and luciferase (reporter gene), were treated for 6 hours at 37 ° C. with an extract according to the invention, as obtained in Example 1, at concentrations ranging from 0.01% to 0.0005% (w / v) and by a positive reference Ter-butylhydroquinone at 20μΜ. At the end of the treatment, the cell mats are lysed, the luciferase activity is assayed by a "Luciferase Assay Kit" from PROMEGA and the protein content of each lysate is determined by the Bradford method (BioRad). Results and conclusion
    The results obtained are shown in Table 4 and in Figure 1. These results show that the extract according to the invention induced an increase in the activity of Nrf2 in the nuclei and therefore a translocation thereof through the nuclear membrane showing activation of this transcription factor.
    This demonstrates that the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
    Table 4 - Nrf2 Activity in HaCaT ARE-Luciferase Activity (RLU = Relative Luciferase Activity)
    * 0.01 <p <0.05; ** 0.001 <ρ · 0.01; *** p <0.001 and ns = not significant vs one-way ANOVA control cells followed by Dunnett B- Gene expression of major markers of Hormesis and cellular detoxification. The effect of an extract according to the invention was studied on the gene expression of various markers involved in the Hormesis pathways and in cell detoxification.
    Material and methods :
    Normal human fibroblasts were treated for 6 h, 24 h and 48 h at 37 ° C with an extract according to the invention, as obtained in Example 1, at 0.005% and 0.002% (w / v). At the end of the treatment, the gene expression of the Hormesis markers (HMOX1, FTL, G6PD and Nrf2) as well as the markers involved in cell detoxification (SOD1 and Catalase) was analyzed by quantitative RT-PCR. real time and standardized against the HPRT household gene (SybrGreen technology).
    The results were analyzed statistically by a one-way ANOVA followed by a Dunnett test (GraphPad Prism Software version 5.02, GraphPad Software, San Diego California USA). Results:
    The results obtained are shown in Table 5. These results show that the extract according to the invention significantly stimulated the gene expression of HMOX1 in 6h and 24h, FTL at three times, G6PD in 6h and 24h, SOD1 in 24h, NrF2 in 24h and 48h and Catalase in 24h.
    This demonstrates that the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
    Table 5 - Gene Expression of Hormesis Markers in Normal Human Fibroblasts Relative Uncertainty
    * 0.01 <p <0.05; ** (), () () 1 p 0.01; *** p <0.001 and ns = not significant vs one-factor ANOVA control cells followed by a Dunnett C test- Production of Heme Oxygenase:
    An extract according to the invention was analyzed on the protein expression of Heme Oxygenase.
    Material and methods :
    Normal human fibroblasts were treated for 24 hours with an extract according to the invention, as obtained in Example 1, at 0.002% and 0.005% (w / v) and Curcumin at 5 and 10 μΜ (Hormetin). reference). At the end of the treatment intracellular Heme Oxygenase 1 (or HMOX1 or HO1) was quantified by an ELISA technique. The staining, proportional to the amount of the marker studied, was measured by reading the optical density (OD) at 450 nm and the value obtained was reduced to the amount of cells obtained by assaying the proteins by the BC Assay technique ( INTERCHIM).
    The results were analyzed statistically by a one-way ANOVA followed by a Dunnett test (GraphPad Prism Software version 5.02, GraphPad Software, San Diego California USA). Results:
    The results obtained are shown in Table 6. These results show that the extract according to the invention has an induction of the same intensity as Curcumin on the production of Heme Oxygenase 1. This result confirms the action of the extract according to the invention we observed when studying the gene expression of this same marker.
    This demonstrates that the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
    Table 6 - Production of HMOX1 by fibroblasts
    *** p <0.001 vs control cells - one-way ANOVA followed by Dunnett test D- Production of Heme Oxygenase under siRNA Nrf2:
    In order to verify whether the activation pathway of heme oxygenase by an extract according to the invention passes through an activation of Nrf2, the induction potential of the production of Heme Oxygenase has been verified in a system where the expression of Nrf2 is blocked (small siRNA interference).
    Material and methods :
    Normal human fibroblasts were pretreated for 24 hours with siRNA Nrf2 and Scrambled siRNA (siRNA control without actions) and then, for each of the preceding conditions, for 24 hours with an extract according to the invention, as obtained in FIG. Example 1, at 0.005% (w / v). At the end of the treatment intracellular Heme Oxygenase 1 (or HMOX1) was quantified by an ELISA technique. Staining, proportional to the amount of the marker studied, was measured by reading the optical density (OD) at 450 nm.
    The results were analyzed statistically by a one-factor ANOVA followed by a Tukey test (GraphPad Prism Software version 5.02, GraphPad Software, San Diego California USA). Results:
    The results obtained are shown in Table 7. These results show that the stimulation of the production of HMOX1 induced by an extract according to the invention is largely decreased (-62%, p <0.001) when the Nrf2 pathway is partially blocked ( siRNA Nrf2). The activity of an extract according to the invention on the production of Heme Oxygenase thus passes well through the Nrf2 pathway.
    This demonstrates that the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
    Table 7 - HMOXl production by fibroblasts - Comparative siRNA Scrambled vs siRNA Nrf2
    *** p <0.001 vs control cells - one-factor ANOVA followed by a Tukey E-Effect test on the production of reactive oxygen species (ROS):
    The antioxidant potential of an extract according to the invention with respect to the induction of reactive oxygen species induced by ΓΗ2Ο2 has been studied.
    Material and methods :
    Normal human keratinocytes were incubated for 24 hours in the presence of an extract according to the invention, as obtained in Example 1, at 0.002%; 0.005% and 0.01% (w / v) or vitamin C at 500μΜ and Quercetin at 10μΜ (reference antioxidants) before incorporation of the H2DCF-DA probe (60-minute incubation).
    The keratinocytes were then stimulated with hydrogen peroxide (H2O2) at 100 μΜ for 20 minutes and the production of ERO (Reactive Oxygen Species) was evaluated by fluorescence measurement.
    The results were analyzed statistically by a one-factor ANOVA followed by a Tukey test (GraphPad Prism Software version 5.02, GraphPad Software, San Diego California USA). Results:
    The results obtained are shown in Table 8. These results show that the extract according to the invention significantly inhibited the production of ERO by keratinocytes in response to oxidative stress induced by hydrogen peroxide (H 2 O 2). This antioxidant activity being of a level equivalent to that of the two antioxidant controls (Vitamin C and Quercetin).
    This demonstrates that the extract according to the invention has antioxidant, anti-radical and anti-aging activity.
    Table 8 - Production of ERO in keratinocytes treated with H2O2
    * * * p <0.001 - One-way ANOVA followed by a Tukey 3 test. Protection against the harmful effects of pollution Previous results have shown that an extract according to the invention stimulates the production of heme oxygenase 1 via the activation of translocation of the Nrf2 transcription factor. Consequently, the extract according to the invention has allowed antioxidant cellular protection via the reduction of the formation of the EROs induced by H202 stress. The extract according to the invention for stimulating the defenses of the skin, we evaluated their protective effect vis-à-vis various environmental stress, here pollution. A- Effect on oxidative stress:
    Material and methods :
    Normal human keratinocytes were treated for 24 hours with an extract according to the invention, as obtained in Example 1, at 0.002% (w / v), vitamin C at 500 μΜ and quercetin at ΙΟμΜ (Antioxidants from reference), Curcumin at ΙΟμΜ (reference Hormetin) or Resveratrol at ΙΟμΜ before incorporation of the H2DCF-DA probe (45-minute incubation).
    The keratinocytes were then stimulated with Benzo-a-pyrene (BaP) at 9 μg / ml for 20 minutes.
    The production of ERO was evaluated by fluorescence measurement.
    The significance of the results was verified by Student's t-test. Results and conclusion:
    The results obtained are shown in Table 9. These results show that the extract according to the invention at 0.002% inhibited the production of ROS by keratinocytes in response to a BaP-induced oxidative stress at 6 and 9 μg / ml.
    Thus the extract according to the invention has a protective effect vis-à-vis the oxidative stress induced by pollution. The extract according to the invention therefore has antioxidant, anti-radical, anti-pollution and anti-aging activity.
    Table 9 - Production of ERO in keratinocytes treated with BaP at 9 μg / ml
    * p <0.05; ** p <0.01; *** p <0.001 and ns = not significant - Student's t test B- Cutaneous structure protection:
    The ability of an extract according to the invention to protect the integrity of the skin (dermis and epidermis) of the harmful effects of pollution has been studied on explants of human skin.
    Material and methods :
    Exponants of human skin, from a 45-year-old woman, have been pretreated for 24 hours by a topical application of a cosmetic formula containing or not (placebo) an extract according to the invention, as obtained in the example 1 to 3%.
    These explants were then again treated with the cosmetic formulas in the presence of Benzo-a-Pyréne (BaP at 20 μΜ) for Protocol 1 or Bap + Nicotine (20 μΜ) for Protocol 2.
    Immunolabelings of different markers of cutaneous structures have been made. Results and conclusion:
    The results obtained are shown in Figures 2 to 7.
    The stress mimicking the pollution induced by BaP +/- Nicotine led to an alteration of the expression of the structural markers studied.
    Under these conditions, the extract according to the invention protected the following epidermal markers: - Claudine 4 (marker of tight junctions / barrier function), - Filaggrine (Marker of the barrier function and precursor of the natural factors of hydration) , and - Loricrin (Marker involved in cell differentiation / barrier function);
    As well as dermal markers such as: - Collagen I (Marker involved in the firmness of the skin), - Elastin (Marker involved in the elasticity of the skin), and - Fibronectin (Marker involved in the structure of the skin) Dermis).
    These results show a real protective effect of the structural integrity of the epidermis and its barrier function as well as the maintenance of a normal structure of the dermis and thus a global protective action of the skin vis-à-vis the environmental pollution . The extract according to the invention therefore has antioxidant, anti-radical, antipollution and anti-aging activity. 4. Protection against deleterious effects related to the sun
    Ultraviolet (UV) and infrared (IR) penetrate more or less deeply into the skin and are responsible, among other things, for a decrease in its firmness and an increase in the amount of free radicals released resulting in premature cutaneous aging. . They are also responsible for melanoma formation and immunodepression of the skin. The protective effect of an extract according to the invention with respect to a stress induced by UV or IR has been studied. A- Protection against DNA damage induced by UV (Cornet Assay):
    The maintenance of the nuclear integrity of the cell, vis-à-vis the UVs, was tested through a test of comets (Cornet Assay).
    Material and methods :
    Normal human keratinocytes were treated for 2 h with an extract according to the invention, as obtained in Example 1, at 0.001% (w / v).
    A Cornet Assay is made according to the method described by "Singh and al" in 1988 and by "De Meo et al" in 1991, which consists in irradiating the cells with light at 4.5 J / cm 2 (0.28 J / cm2 of UVA, 0.08 J / cm 2 of UVB and 4.14 J / cm 2 of visible light) corresponding to an exposure of 1 to 3 min to the sun in summer. Then an electrophoretic gel migration of agarose DNA on a gel.
    A relative value of χ2 OTM is calculated using software "Systat Software", which is directly proportional to the size of the comet and therefore the degree of protection of the asset vis-à-vis the UV.
    The significance of the results was verified by an analysis of variance on SigmaPlot software (version 11.0, Systat Software, Chicago, IL, USA). Results and conclusion:
    The results are shown in Table 10 and in Figure 8
    These results show that the extract according to the invention at 0.001%, protected the keratinocytes against DNA damage induced by UV irradiation (54% protection, p <0.001). The extract according to the invention therefore has antioxidant, anti-radical, antipollution and anti-aging activity.
    Table 10 - Percentage of cell protection against UV
    *** p <0.001 vs non-irradiated cells and vs cells irradiated at 4.5J / cm2. Statistics on SigmaPlot B- Inhibition of the production of MMPI induced by the IR Infrared (IR), which represent more than half of the solar spectrum, can induce the degradation of the dermal matrix, contributing to the cutaneous aging, by stimulating the production of proteases such as MMPI.
    The ability of an extract according to the invention to protect dermal cells from the harmful effects of IR was studied by evaluating the production of MMPI.
    Material and methods :
    Normal Human Fibroblasts (FHN) were incubated in the presence of an extract according to the invention, as obtained in Example 1, at 0.001% or by dexamethasone at 10 -7 M (anti-inflammatory reference) for 48 hours at following irradiation of 1 h by infrared (0.57 kJ / cm 2).
    After incubation, the supernatants are recovered in order to assay the released MMPI (Kit ELIS A, R & D Systems).
    The significance of the results was verified by Student's t-test. Results and conclusion:
    The results are shown in Table 11. These results show that the 0.001% extract according to the invention significantly inhibited the production of Infra Red MMPI in normal human Fibroblasts. The extract according to the invention therefore has antioxidant, anti-radical, antipollution and anti-aging activity.
    Table 11 - IR-induced MMPI production in normal human fibroblasts
    * p <0.05; * * * p <0.001 vs irradiated cells 5. Protection against the effects of chemical stress
    Effect on PMA 2 production induced by PMA:
    The anti-inflammatory protection of an extract according to the invention with respect to a chemical molecule, PMA, was studied by means of the Prostaglandin 2 (PGE2) salting analysis.
    Material and methods :
    Normal human keratinocytes were pretreated with an extract according to the invention, as obtained in Example 1, at 0.002% and 0.005% and with Indomethacin at 10 μM (anti-inflammatory control of the pathway). prostaglandins) for 24h at 37 ° C., in order to be able to measure a level of protection of the active ingredient with respect to an inflammation of PMA (Phorbol 12-myristate 13-acetate) at 0.1 μg / ml used on these same cell mat for 24 hours more. At the end of the treatment the supernatants are harvested and a Prostaglandin E2 (PGE2; RetD Systems) assay is performed. The color, proportional to the amount of PGE2, was measured by reading the optical density (OD) at 450 nm.
    The significance of the results was verified by Student's t-test. Results:
    The results are shown in Table 12. These results show that the extract according to the invention at both concentrations significantly decreased the release of PGE2 with respect to an induction by PMA at 0.1 μg / ml. . The extract according to the invention therefore has antioxidant, anti-radical, antipollution and anti-aging activity.
    Table 2 - Production of PGE2 in keratinocytes treated with PMA
    ** 0.001 <p <0.01 and *** p <0.001 vs PMA stimulated cells Student t test 6. Protection from the effects of aging Repeated action of environmental stress, such as, pollution, adverse effects of the sun, chemical molecules and all other forms of inductions of an oxidative stress, causes a degradation of the dermal matrix and thus a premature cutaneous aging.
    An extract according to the invention was analyzed on a model of cellular aging in order to analyze their actions with respect to proteins which are under-expressed or overexpressed with age.
    Material and methods :
    Keratinocytes are cultured, and trypsinated every week, for 4 weeks in a culture medium inducing an aging phenotype ("pro-age" medium) in the presence or absence of an extract according to the invention, such that obtained in Example 1 at 0.000025% DM.
    After 3 weeks of culture / passage proteomic analysis is performed. These are involved in various cellular pathways grouped into 6 areas: metabolism, apoptosis, detoxification, protein catabolism and protein synthesis. Results and conclusion:
    The results are shown in Table 13. In this context of induction of aging, the extract according to the invention has stimulated and / or protected the expression of several proteins mainly involved in detoxification / cellular protection and in immune defenses. : Detoxification and cellular protection: • Stimulation of Peroxiredoxin 2 (PRDX2): an antioxidant enzyme that plays a role in cell protection against damage caused by intracellular EROs. • Stimulation of Carbonyl Reductase 1 (CBR1): dehydrogenase / reductase to reduce carbonyl compounds (drugs) and intervenes in the detoxification during lipid peroxidation. This is inhibited under "pro-age" conditions and stimulated by the extract according to the invention under these conditions. • Inhibition of Aldehyde Dehydrogenase 2 (ALDH2): a mitochondrial enzyme that plays a role in cell protection and differentiation that will catalyze / detoxify aldehyde / carbonyl molecules (drugs, pollution ...). This protein is stimulated under "pro-age" conditions, the extract according to the invention restores its level of expression to a basal level. • Stimulation of Fatty Acid Binding Protein 5 (FABP5): chaperone protein mainly expressed in the epidermis and involved in the regulation of lipid homeostasis and thus playing a role in the barrier function. The "pro-age" conditions inhibit its expression, which is restored by the polyphenols of Maracuja. • Stimulation of subunits β2 and β6 (PSMB2 and PSMB6): The Proteasome is involved in the elimination of altered / oxidized proteins and in the renewal of intracellular proteins. It consists of α and β subunits that, among other things, cut the altered proteins at glutamine (β6) and trypsin (β2) levels. Age decreases the activity of Proteasome resulting in an accumulation of altered / oxidized proteins; this effect of age is found under "proâge" conditions and under these conditions the extract according to the invention stimulates the expression of these two subunits of the proteasome. Immune defense: • Inhibition of Beta-2-microglobulin (B2MG): small surface protein (epidermis) involved in the immune response. It is part of the major histocompatibility complex and is overexpressed in pathological conditions which will induce the production of interleukins, in particular 6 and 8, as well as 10 which is an immunosuppressive interleukin. Here, under conditions inducing aging, its expression is increased. The extract according to the invention prevents this increase. • Lectin Inhibition, mannose-binding, 1 (LMAN1): a protein that is part of the innate immune response by allowing phagocytosis of apoptotic cells and pathogens. A deficiency in this gene involves an increase in cellular debris in the skin. It is not present in the basal state and is increased in inflammatory condition (Ex: UV). In "pro-age" conditions, its expression is increased and modulated under the action of the extract according to the invention.
    Table 13 - Protein Expression of Markers Involved in Detoxification and Immunity (in%)
    7. Conclusion
    These various tests show an anti-inflammatory, anti-oxidant, anti-pollution and therefore anti-aging effect of the polyphenolic extract according to the invention.
    Example 3: Compositions for topical application
    Several compositions for topical application are presented below. The polyphenol extract of passionflower seeds, of example 1 or 2, can be incorporated into various cosmetic products, such as cleaning waters, oil-in-water emulsions, water-in-oil emulsions, oils, milks, lotions, shampoos, foaming products and sprays, the compositions of which are given below as examples.
    CLEANING WATER SENSITIVE SKIN
    ANTI-AGING EMULSION
    权利要求:
    Claims (13)
    [1" id="c-fr-0001]
    1. Polyphenol extract of passionflower seeds, in particular seeds of Passiflora incamata or Passiflora edulis, comprising at least 30% by weight of polyphenols, expressed as gallic acid equivalent, relative to the weight of the dry extract.
    [2" id="c-fr-0002]
    2. Extract according to claim 1, comprising at least 35%, advantageously at least 40%, by weight of polyphenols, expressed in gallic acid equivalent, relative to the weight of the dry extract.
    [3" id="c-fr-0003]
    3. Extract according to claim 1 or 2, wherein at least 50% by weight of said polyphenols are catechin derivatives, expressed in gallic acid equivalent, relative to the weight of polyphenols in the dry extract.
    [4" id="c-fr-0004]
    4. Extract according to any one of claims 1 to 3, wherein said extract comprises at least 10% by weight of organic acids, especially acetic acid, malic acid, citric acid or mixtures thereof, by relative to the weight of the dry extract.
    [5" id="c-fr-0005]
    5. Extract according to any one of claims 1 to 4, characterized in that it is obtained by solid / liquid extraction of passionflower seeds in a solvent selected from water, glycerols, glycols, and mixtures thereof.
    [6" id="c-fr-0006]
    6. Extract according to any one of claims 1 to 5, characterized in that it is obtained by solid / liquid extraction of passionflower seeds in a solvent selected from water / glycerol binary mixtures, water / glycol, and mixtures thereof. , advantageously in a proportion of between 30 and 90% glycerol and / or glycol in water.
    [7" id="c-fr-0007]
    7. Process for the preparation of a polyphenol extract of passionflower seeds as defined in any one of claims 1 to 6, said process comprising at least one solid / liquid extraction step in a solvent chosen from water, glycerols, glycols, and mixtures thereof.
    [8" id="c-fr-0008]
    8. Method according to claim 7, characterized in that it comprises the following successive steps: a) crushing seeds; b) optionally delipidation of the seeds, preferably by pressing, by ethanolic extraction or by supercritical CO2 extraction; c) solid / liquid extraction of the crushed seeds and optionally delipidated in a solvent selected from water, glycerols, glycols, and mixtures thereof; d) separation of the solid phase and the liquid phase by decantation, and / or centrifugation and / or successive filtrations; and e) optionally drying the extract obtained in step d).
    [9" id="c-fr-0009]
    9. The method of claim 7 or 8, characterized in that said solid / liquid extraction solvent is selected from water / glycerol binary mixtures, water / glycol, and mixtures thereof, preferably in a proportion of between 30 and 90%. glycerol and / or glycol in the water.
    [10" id="c-fr-0010]
    10. A composition comprising as an active principle a polyphenol extract of passionflower seeds as defined in any one of claims 1 to 6 or an extract obtainable by the method according to any one of the claims. 7 to 9, and advantageously a suitable excipient.
    [11" id="c-fr-0011]
    11. Composition according to claim 10, comprising from 0.001 to 10% by weight, advantageously from 0.01 to 5% by weight, of said polyphenol extract of passionflower seeds, the weight of the extract being expressed as dry extract, relative to to the total weight of the composition.
    [12" id="c-fr-0012]
    12. Extract according to any one of claims 1 to 6 or extract obtainable by the method according to any one of claims 7 to 9 or composition according to any one of claims 10 and 11 for its use to prevent and / or treat: - disorders or pathologies of the skin and / or mucous membranes and / or integuments, advantageously inflammatory reactions, oxidation reactions, disorders related to radical attacks related or not to pollution, disorders of the barrier or homeostasis, aging, in particular chronological and / or actinic aging, of the skin and / or mucous membranes and / or superficial body growths, and / or - vascular disorders, and / or - alterations adipose tissue.
    [13" id="c-fr-0013]
    13. Process for the cosmetic care of the skin and / or superficial body growths and / or mucous membranes, with a view to improving their state and / or their appearance, comprising administering an extract as defined in any one of claims 1 to 6 or an extract obtainable by the method according to any one of claims 7 to 9 or a cosmetic composition as defined according to any one of claims 10 and 11.
    类似技术:
    公开号 | 公开日 | 专利标题
    FR3045380B1|2019-08-23|EXTRACT OF PASSIFLORE SEEDS AND COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITIONS COMPRISING SAME.
    FR2754713A1|1998-04-24|USE OF COMPLEXES FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF SENSITIVE SKIN, PREPARATION METHOD AND HYPOALLERGENIC COMPOSITIONS
    WO2019122408A1|2019-06-27|Kapok tree flower extract, and cosmetic, pharmaceutical or dermatological compositions containing same
    EP3082464A1|2016-10-26|Composition comprising grape extracts of the tannat grape or the cannonau grape, extraction method and uses thereof
    FR3023482A1|2016-01-15|OMBELLIFER HYDROGLYCERIN EXTRACT FOR COSMETIC USE
    EP3113850B1|2019-06-26|Skin-brightening cosmetic composition
    EP3407867A1|2018-12-05|Dermatological or cosmetic compositions containing a polyphenol-enriched extract of vitex negundo
    CA2968754A1|2016-06-02|Peptide and glycoside extract of schizandra fruit and improvement in the response of the cutaneous neurosensory system
    FR3066916B1|2019-08-16|VEGETABLE COMPLEX BASED ON BIRCH SEVE AND AQUEOUS CHAGA EXTRACT AND COSMETIC APPLICATIONS
    FR3055214B1|2019-06-21|LIGHTENING COSMETIC COMPOSITION
    FR3095759A1|2020-11-13|Agrimony extract as an anti-pollution agent
    FR3048882A1|2017-09-22|COCO NUT SHELL EXTRACTS, COMPOSITIONS INCLUDING THE SAME AND USES THEREOF
    FR3059236A1|2018-06-01|EXTRACTS FROM PLANTS OF THE GENUS TAGETES AND USES THEREOF
    FR3052979A1|2017-12-29|BIOMIMETIC COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF ARGAN OIL AND HYDROGLYCERIN EXTRACTS OF BROWN ALGAE, ALARIA ESCULENTA AND MYRIT
    FR3061013A1|2018-06-29|COMPOSITION COMPRISING DIGENEASIDE, PROCESS FOR OBTAINING SAME AND COSMETIC, VETERINARY OR NUTRACEUTICAL USE
    WO2018002453A1|2018-01-04|Composition for combating the signs of ageing of the skin and hair and nails
    FR3049864A1|2017-10-13|VEGETABLE EXTRACT FROM A PLANT OF THE GENUS AERVA, COMPOSITION CONTAINING SAME AND USE OF SAID VEGETABLE EXTRACT
    FR3095760A1|2020-11-13|Agrimony extract as an anti-pollution agent
    FR3031457B1|2019-06-07|ABBA ALBA FIR TREE OIL, COMPOSITIONS AND USES
    WO2021234159A1|2021-11-25|Moringa peregrina seed extract rich in 2,5-diformylfuran, process for obtaining same and use thereof in cosmetic compositions
    FR3110419A1|2021-11-26|Moringa peregrinariche seed extract in 2,5-diformylfuran, its process for obtaining and its use in cosmetic compositions
    FR3106754A1|2021-08-06|PROCESS FOR OBTAINING AN AQUEOUS LAVENDER EXTRACT, COMPOSITIONS INCLUDING SUCH EXTRACT AND THEIR COSMETIC USES
    FR3100717A1|2021-03-19|DEPIGMENTING COSMETIC COMPOSITION
    FR3099370A1|2021-02-05|Extract of rose stems, composition comprising the extract and cosmetic use of said extract and of the composition
    FR3102930A1|2021-05-14|Cosmetic use of aromatic raw material extract in cosmetics to protect the skin against blue light
    同族专利:
    公开号 | 公开日
    FR3045380B1|2019-08-23|
    JP6907211B2|2021-07-21|
    US20190000902A1|2019-01-03|
    CN108697610A|2018-10-23|
    US20210236574A1|2021-08-05|
    JP2018538332A|2018-12-27|
    KR20180121877A|2018-11-09|
    EP3393444A1|2018-10-31|
    WO2017108978A1|2017-06-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR3010906A1|2013-09-25|2015-03-27|Expanscience Lab|LIPID EXTRACT OF PASSIFLOWER SEEDS|
    KR20150064314A|2013-12-03|2015-06-11|한국콜마주식회사|Cosmetic Composition Comprising Mangifera indica L. Extract, Passiflora edulis Sims Extract, Hylocereus undatus Britt. and Rose Extract, Actinidia chinensis Planch. Extract and Annona Squamosa Extract|EP3607997A1|2018-08-10|2020-02-12|Société De Recherche Cosmétique S.à.r.L.|Cosmetic composition comprising an extract of passion flower and edelweiss cells and uses|
    EP3763355A1|2019-07-12|2021-01-13|Laboratoires Expanscience|Composition comprising passion flower seed polyphenols, avocado peptides and an extract of witch hazel and use for treating and/or preventing stretch marks|CA2833436C|2011-04-22|2016-08-09|Morinaga & Co., Ltd.|Composition containing scirpusin b, and process for producing composition containing scirpusin b|
    CN104193595A|2014-09-05|2014-12-10|南京泽朗生物科技有限公司|Method for extracting piceatannol from passionflower seeds|
    CN104230672A|2014-09-05|2014-12-24|南京泽朗生物科技有限公司|Method for extracting piceatannol from fresh passion fruit seeds|FR3010906B1|2013-09-25|2016-12-23|Expanscience Lab|LIPID EXTRACT OF PASSIFLOWER SEEDS|
    TWI719503B|2019-06-13|2021-02-21|大江生醫股份有限公司|Use of passion fruit seed extracts for upregulating gene expression of tph1, ddc, and aanat|
    US20210299016A1|2020-03-30|2021-09-30|Colgate-Palmolive Company|Sulfate-free personal care compositions and methods for preventing and treating pollution damage to skin|
    WO2021207813A1|2020-04-15|2021-10-21|Beraca Ingredientes Naturais S.A.|Terpene-containing composition and its cosmetic use|
    CN112076120B|2020-09-12|2021-04-30|广州惜颜生物科技有限公司|Skin care composition for repairing sensitive skin and preparation method thereof|
    法律状态:
    2016-12-07| PLFP| Fee payment|Year of fee payment: 2 |
    2017-06-23| PLSC| Publication of the preliminary search report|Effective date: 20170623 |
    2017-12-13| PLFP| Fee payment|Year of fee payment: 3 |
    2018-12-07| PLFP| Fee payment|Year of fee payment: 4 |
    2019-12-12| PLFP| Fee payment|Year of fee payment: 5 |
    2020-12-14| PLFP| Fee payment|Year of fee payment: 6 |
    2021-11-10| PLFP| Fee payment|Year of fee payment: 7 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1562949|2015-12-21|
    FR1562949A|FR3045380B1|2015-12-21|2015-12-21|EXTRACT OF PASSIFLORE SEEDS AND COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITIONS COMPRISING SAME.|FR1562949A| FR3045380B1|2015-12-21|2015-12-21|EXTRACT OF PASSIFLORE SEEDS AND COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITIONS COMPRISING SAME.|
    US16/064,312| US20190000902A1|2015-12-21|2016-12-21|Passion flower seed extract, and cosmetic, pharmaceutical or dermatological compositions containing same|
    JP2018532411A| JP6907211B2|2015-12-21|2016-12-21|Passionflower seed extract and cosmetic, pharmaceutical or dermatological compositions containing it|
    PCT/EP2016/082216| WO2017108978A1|2015-12-21|2016-12-21|Passion flower seed extract, and cosmetic, pharmaceutical or dermatological compositions containing same|
    CN201680081825.8A| CN108697610A|2015-12-21|2016-12-21|Passionflower seed extract and cosmetics, drug or dermatological compositions comprising it|
    EP16812977.3A| EP3393444A1|2015-12-21|2016-12-21|Passion flower seed extract, and cosmetic, pharmaceutical or dermatological compositions containing same|
    KR1020187020626A| KR20180121877A|2015-12-21|2016-12-21|Clock flower seed extract and cosmetic, pharmaceutical or dermatological compositions comprising it|
    US17/239,042| US20210236574A1|2015-12-21|2021-04-23|Passion flower seed extract, and cosmetic, pharmaceutical or dermatological compositions containing same|
    [返回顶部]